tradingkey.logo
Search
Markets
Watchlist
News
Analysis
Tools
Stock Screener
English
繁体中文
ไทย
Tiếng việt
简体中文
Español
Português
Deutsch
한국어
日本語
tradingkey.logo
Search

Supernus Pharmaceuticals Inc

SUPN
Add to Watchlist
44.630USD
-0.980-2.15%
Close 07-31 16:00（ET）Quotes delayed by 15 min
2.59BMarket Cap
LossP/E TTM

Supernus Pharmaceuticals Inc

44.630
-0.980-2.15%
Overview
Financials
Discussions
Analysis
Company
Financial SummaryIncome StatementBalance SheetCash Flow Statement

Overview

Financials

Discussions

Analysis

Company

Financial SummaryIncome StatementBalance SheetCash Flow Statement

SUPN Financials

See Supernus Pharmaceuticals Inc's financials through an all-in-one data dashboard designed for smart investors. This provides you with financial analysis by organizing complex financial statements into customizable views. Access the latest annual financial report or break down performance quarter-by-quarter using the income statement, balance sheet, and cash flow statement. With real-time financial indicators at your fingertips, monitoring a company's market health over time has never been easier.

Supernus Pharmaceuticals Inc Earnings Date

Latest Release
Aug 4, 2026
EPS / Forecast
--/0.42
Revenue / Forecast
--/204.96M
See Upcoming Earnings >>
Period
FY2025 Earnings
Revenue(YoY)
718.95M
8.63%
EPS(YoY)
-0.68
-150.94%
Analyst Rating
BUY
2026/08/02
Quarterly
Quarterly+Annual
Quarterly
Annual
YOY
Hide blank rows
FY2026Q1
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021Q4
FY2021Q3
FY2021Q2
Financial Indicators
EPS
81.21%-0.04
-125.88%-0.07
-214.29%-0.80
10.86%0.40
-9467.70%-0.21
1185.30%0.28
338.61%0.70
2475.41%0.36
-99.27%0.00
-95.43%0.02
---0.29
---0.02
--0.31
--0.47
--0.66
----
----
----
----
----
Revenue
38.63%207.71M
21.48%211.57M
9.34%192.10M
-1.71%165.45M
4.30%149.82M
5.99%174.16M
14.17%175.69M
24.17%168.32M
-6.58%143.64M
-1.80%164.31M
-13.24%153.88M
-20.28%135.56M
0.82%153.76M
5.20%167.33M
19.46%177.35M
20.32%170.05M
16.48%152.51M
10.79%159.05M
-4.30%148.46M
11.52%141.33M
Net Profit
80.61%-2.29M
-126.78%-4.11M
-217.20%-45.12M
12.97%22.50M
-9637.90%-11.83M
1204.51%15.33M
340.97%38.50M
2496.63%19.92M
-99.27%124.00K
-95.39%1.18M
-1013.44%-15.98M
-110.57%-831.00K
-33.84%16.95M
943.45%25.48M
-91.89%1.75M
-66.85%7.87M
349.88%25.62M
-92.06%2.44M
-46.09%21.56M
-31.56%23.73M
Net Margin
86.01%-1.10%
-122.05%-1.94%
-207.18%-23.49%
14.93%13.60%
-9244.96%-7.89%
1130.78%8.80%
311.06%21.91%
2030.16%11.83%
-99.22%0.09%
-95.30%0.72%
---10.38%
---0.61%
--11.02%
--15.23%
--7.05%
----
----
----
----
----
Gross Margin
0.16%76.39%
-1.53%78.43%
-1.82%77.47%
-0.21%77.25%
2.20%76.27%
5.87%79.65%
7.41%78.90%
11.21%77.41%
4.00%74.63%
1.79%75.23%
--73.46%
--69.61%
--71.76%
--73.91%
--74.76%
----
----
----
----
----
Debt to assets ratio
----
----
----
----
----
----
----
----
----
-100.00%0.00%
--0.00%
--0.00%
--26.84%
--23.61%
--23.71%
----
----
----
----
----
Income Statement
Revenue
38.63%207.71M
21.48%211.57M
9.34%192.10M
-1.71%165.45M
4.30%149.82M
5.99%174.16M
14.17%175.69M
24.17%168.32M
-6.58%143.64M
-1.80%164.31M
-13.24%153.88M
-20.28%135.56M
0.82%153.76M
5.20%167.33M
19.46%177.35M
20.32%170.05M
16.48%152.51M
10.79%159.05M
-4.30%148.46M
11.52%141.33M
Operating profit
-128.85%-5.94M
-42.03%17.77M
-76.71%9.28M
-33.34%12.14M
38.89%-2.60M
73.46%30.66M
389.42%39.83M
203.57%18.21M
-220.37%-4.25M
-48.52%17.68M
634.34%8.14M
-255.01%-17.59M
34.08%3.53M
16.32%34.33M
-104.66%-1.52M
-55.27%11.35M
-81.51%2.63M
-34.40%29.52M
-41.78%32.68M
-52.10%25.36M
Net Profit
80.61%-2.29M
-126.78%-4.11M
-217.20%-45.12M
12.97%22.50M
-9637.90%-11.83M
1204.51%15.33M
340.97%38.50M
2496.63%19.92M
-99.27%124.00K
-95.39%1.18M
-1013.44%-15.98M
-110.57%-831.00K
-33.84%16.95M
943.45%25.48M
-91.89%1.75M
-66.85%7.87M
349.88%25.62M
-92.06%2.44M
-46.09%21.56M
-31.56%23.73M
Balance Sheet
Current assets
6.40%731.58M
-6.11%644.18M
-7.20%593.89M
25.02%738.87M
26.32%687.58M
39.13%686.07M
42.43%640.00M
39.54%591.00M
-38.38%544.32M
-32.83%493.11M
-32.31%449.36M
-32.25%423.54M
55.38%883.34M
22.04%734.15M
-0.67%663.89M
-2.21%625.12M
-2.99%568.52M
-4.57%601.59M
21.08%668.38M
14.73%639.24M
Total current liabilities
32.71%373.93M
15.65%338.17M
13.42%330.63M
-7.22%286.36M
-10.42%281.77M
0.76%292.40M
1.38%291.51M
22.20%308.66M
-57.00%314.55M
-57.82%290.20M
-60.39%287.53M
-65.66%252.59M
157.08%731.54M
118.14%687.96M
209.31%725.99M
159.50%735.54M
18.17%284.56M
28.67%315.38M
-21.66%234.71M
5.26%283.45M
Total assets
11.39%1.50B
6.18%1.45B
5.74%1.42B
5.06%1.38B
3.31%1.35B
7.08%1.37B
4.48%1.34B
1.76%1.32B
-27.22%1.30B
-24.95%1.28B
-24.10%1.29B
-23.71%1.29B
9.29%1.79B
0.79%1.70B
8.88%1.69B
7.75%1.69B
8.76%1.64B
12.30%1.69B
2.98%1.56B
5.50%1.57B
Total liabilities
33.90%423.92M
17.63%390.93M
10.29%370.09M
-11.13%318.50M
-15.56%316.58M
-6.69%332.34M
-10.03%335.55M
-3.97%358.38M
-57.38%374.92M
-56.37%356.16M
-55.62%372.97M
-56.28%373.19M
8.46%879.66M
-6.53%816.30M
12.86%840.33M
8.39%853.54M
7.71%811.07M
15.02%873.30M
-7.06%744.57M
-4.55%787.48M
Total equity
4.47%1.08B
2.51%1.06B
4.22%1.05B
11.12%1.06B
10.93%1.03B
12.39%1.04B
10.41%1.01B
4.08%957.45M
1.87%929.17M
3.98%921.52M
6.96%912.19M
9.33%919.91M
10.10%912.15M
8.62%886.20M
5.22%852.80M
7.11%841.43M
9.81%828.45M
9.53%815.85M
14.33%810.47M
17.96%785.58M
Cash Flow Statement
Net operating income
117.41%66.52M
-55.27%19.86M
-215.22%-61.66M
64.31%58.53M
-20.32%30.60M
-1.23%44.41M
49.18%53.52M
288.75%35.62M
-21.83%38.40M
63.10%44.96M
159.19%35.88M
-126.54%-18.87M
1041.93%49.13M
-43.47%27.56M
436.76%13.84M
53.69%71.12M
-88.12%4.30M
52.70%48.76M
-173.41%-4.11M
-49.68%46.27M
Net investment
-151.50%-19.22M
-306.00%-51.31M
163.25%48.71M
37.01%-30.61M
172.29%37.32M
80.85%-12.64M
-322.36%-77.01M
-180.59%-48.59M
-121.53%-51.62M
-35.30%-65.98M
142.12%34.63M
484.57%60.30M
442.61%239.78M
-164.05%-48.77M
-1341.65%-82.23M
80.62%-15.68M
2.04%-69.99M
54.28%76.13M
49.53%-5.70M
25.22%-80.89M
Net financing
142.60%9.12M
44.75%8.53M
585.14%21.07M
-43.61%935.00K
-1462.99%-21.40M
439.38%5.89M
1436.96%3.08M
100.35%1.66M
-98.04%1.57M
-61.40%1.09M
-103.56%-230.00K
-21169.78%-478.92M
463.86%80.17M
102.07%2.83M
387.54%6.46M
-17.32%2.27M
-1080.60%-22.03M
-4555.52%-136.74M
235.24%1.32M
91.30%2.75M

FAQs

What is the total revenue of Supernus Pharmaceuticals Inc?

According to Supernus Pharmaceuticals Inc's FY2025 earnings report, its total revenue reached 718.95M, with a year-on-year change of 661.82M.

What are the current assets of Supernus Pharmaceuticals Inc?

According to Supernus Pharmaceuticals Inc's FY2025 earnings report, its current assets were 644.18M, with a year-on-year change of -6.11.

What are the total assets of Supernus Pharmaceuticals Inc?

According to Supernus Pharmaceuticals Inc's FY2025 earnings report, its total assets of Supernus Pharmaceuticals Inc were 1.45B, with a year-on-year change of 6.18.

What are the total liabilities of Supernus Pharmaceuticals Inc?

According to Supernus Pharmaceuticals Inc's FY2025 earnings report, its total liabilities of Supernus Pharmaceuticals Inc were 390.93M, with a year-on-year change of 17.63.

What is the total equity of Supernus Pharmaceuticals Inc?

According to Supernus Pharmaceuticals Inc's FY2025 earnings report, its total equity of Supernus Pharmaceuticals Inc was 1.06B, with a year-on-year change of 2.51.

What is the net operating income of Supernus Pharmaceuticals Inc?

According to Supernus Pharmaceuticals Inc's FY2025 earnings report, its net operating income of Supernus Pharmaceuticals Inc was 37.96M, with a year-on-year change of -55.05.

What is the net investment of Supernus Pharmaceuticals Inc?

According to Supernus Pharmaceuticals Inc's FY2025 earnings report, its net investment of Supernus Pharmaceuticals Inc was 4.11M, with a year-on-year change of 102.16.

What is the net financing of Supernus Pharmaceuticals Inc?

According to Supernus Pharmaceuticals Inc's FY2025 earnings report, its net financing of Supernus Pharmaceuticals Inc was 9.13M, with a year-on-year change of -25.12.

What is the Earnings Per Share (EPS) of Supernus Pharmaceuticals Inc?

According to Supernus Pharmaceuticals Inc's FY2025 earnings report, its Earnings Per Share (EPS) was -0.68, with a year-on-year change of -150.94.

What is the net income of Supernus Pharmaceuticals Inc?

According to Supernus Pharmaceuticals Inc's FY2025 earnings report, its net income was -38.55M, with a year-on-year change of -152.19.

What is the net margin of Supernus Pharmaceuticals Inc?

According to Supernus Pharmaceuticals Inc's FY2025 earnings report, its net profit margin was -5.36, with a year-on-year change of -148.04.

What is the gross margin of Supernus Pharmaceuticals Inc?

According to Supernus Pharmaceuticals Inc's FY2025 earnings report, its gross margin was 77.45, with a year-on-year change of -0.44.

What is the Return on Equity (ROE) of Supernus Pharmaceuticals Inc?

According to Supernus Pharmaceuticals Inc's FY2025 earnings report, its Return on Equity (ROE) was -3.68, with a year-on-year change of -148.70.

What is the Return on Assets (ROA) of Supernus Pharmaceuticals Inc?

According to Supernus Pharmaceuticals Inc's FY2025 earnings report, its Return on Assets (ROA) was -2.73, with a year-on-year change of -148.95.

What is the operating profit of Supernus Pharmaceuticals Inc?

According to Supernus Pharmaceuticals Inc's FY2025 earnings report, its operating profit was 37.96M, with a year-on-year change of -55.05.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.
General Terms of Use
Privacy Policy
Cookie Policy